<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Krawczyk PS</submitter><funding>European Research Council</funding><pagination>984-992</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12095053</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>641(8064)</volume><pubmed_abstract>Despite the widespread use of mRNA vaccines against COVID-19, little is known about the metabolism of therapeutic RNAs. Here we use nanopore sequencing&lt;sup>1-3&lt;/sup> to analyse individual therapeutic mRNA molecules, focusing on their poly(A) tails. We show that the Moderna mRNA-1273 vaccine&lt;sup>4&lt;/sup> has a poly(A) tail of around 100 nucleotides, followed by an mΨCmΨAG sequence. In cell lines, mRNA-1273 undergoes rapid degradation initiated by mΨCmΨAG removal, followed by CCR4-NOT-mediated deadenylation. However, in medically relevant preclinical models, particularly in macrophages, mRNA-1273 poly(A) tails are extended to up to 200 nucleotides by the TENT5A poly(A) polymerase&lt;sup>5-7&lt;/sup>, which is induced by the vaccine. Re-adenylation, which stabilizes target mRNAs, is consistently obs</pubmed_abstract><journal>Nature</journal><pubmed_title>Re-adenylation by TENT5A enhances efficacy of SARS-CoV-2 mRNA vaccines.</pubmed_title><pmcid>PMC12095053</pmcid><funding_grant_id>101097317</funding_grant_id><pubmed_authors>Affek K</pubmed_authors><pubmed_authors>Jelen S</pubmed_authors><pubmed_authors>Brouze A</pubmed_authors><pubmed_authors>Jemielity J</pubmed_authors><pubmed_authors>Tudek A</pubmed_authors><pubmed_authors>Nowis D</pubmed_authors><pubmed_authors>Golab J</pubmed_authors><pubmed_authors>Wesolowska A</pubmed_authors><pubmed_authors>Orzel W</pubmed_authors><pubmed_authors>Antczak W</pubmed_authors><pubmed_authors>Turowski P</pubmed_authors><pubmed_authors>Kasztelan K</pubmed_authors><pubmed_authors>Guminska N</pubmed_authors><pubmed_authors>Spiewla T</pubmed_authors><pubmed_authors>Mroczek S</pubmed_authors><pubmed_authors>Mazur M</pubmed_authors><pubmed_authors>Tarkowski B</pubmed_authors><pubmed_authors>Matylla-Kulinska K</pubmed_authors><pubmed_authors>Sroka M</pubmed_authors><pubmed_authors>Kusio-Kobialka M</pubmed_authors><pubmed_authors>Owczarek EP</pubmed_authors><pubmed_authors>Gewartowska O</pubmed_authors><pubmed_authors>Krawczyk PS</pubmed_authors><pubmed_authors>Dziembowski A</pubmed_authors><pubmed_authors>Kowalska J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Re-adenylation by TENT5A enhances efficacy of SARS-CoV-2 mRNA vaccines.</name><description>Despite the widespread use of mRNA vaccines against COVID-19, little is known about the metabolism of therapeutic RNAs. Here we use nanopore sequencing&lt;sup>1-3&lt;/sup> to analyse individual therapeutic mRNA molecules, focusing on their poly(A) tails. We show that the Moderna mRNA-1273 vaccine&lt;sup>4&lt;/sup> has a poly(A) tail of around 100 nucleotides, followed by an mΨCmΨAG sequence. In cell lines, mRNA-1273 undergoes rapid degradation initiated by mΨCmΨAG removal, followed by CCR4-NOT-mediated deadenylation. However, in medically relevant preclinical models, particularly in macrophages, mRNA-1273 poly(A) tails are extended to up to 200 nucleotides by the TENT5A poly(A) polymerase&lt;sup>5-7&lt;/sup>, which is induced by the vaccine. Re-adenylation, which stabilizes target mRNAs, is consistently obs</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 May</publication><modification>2026-06-02T20:45:12.516Z</modification><creation>2026-04-20T03:10:50.438Z</creation></dates><accession>S-EPMC12095053</accession><cross_references><pubmed>40240603</pubmed><doi>10.1038/s41586-025-08842-1</doi></cross_references></HashMap>